Rob S.

Trichome cap sizes in cannabis are pivotal in maximizing oil production, terpene storage, and cannabinoid synthesis. These microscopic structures act as the plant's chemical factories, with larger caps enhancing the potency and yield of essential compounds. Understanding and optimizing trichome cap sizes can revolutionize the efficiency and quality of #cannabis cultivation, driving advancements in medicinal and recreational applications.

50

15 comentários

Unveiling New Marijuana - Cannabis Cannabinoids: THCP and CBDP Marijuana research is an ever-evolving area, continuously revealing brand-new cannabinoids with one-of-a-kind residential or commercial properties. Amongst the current explorations are THCP (tetrahydrocannabiphorol) and CBDP (cannabidiphorol). These unique substances promise to reshape our understanding of cannabis and its prospective benefits. This blog delves into the fascinating world of THCP and CBDP, exploring their chemical structures, prospective benefits, present research study, and future ramifications. With extensive testing from accredited labs like a Third Party CBDTesting Lab, these discoveries hold terrific pledge for both the cannabis market and medical applications. What are THCP and CBDP? THCP and CBDP Defined THCP: THCP, or tetrahydrocannabiphorol, is a newly uncovered cannabinoid that resembles THC yet is possibly a lot more potent. This increased effectiveness is thought to arise from its distinct chemical structure, which allows it to connect extra highly with the body's endocannabinoid system. THCP's discovery opens the door to brand-new possibilities in cannabis-based therapies, specifically in locations where high strength is helpful. CBDP: CBDP, or cannabidiphorol, is one more newly recognized cannabinoid that carefully resembles CBD. Nonetheless, minor variations in its framework may lead to one-of-a-kind therapeutic advantages not seen with conventional CBD. This could consist of enhanced anti-inflammatory properties or various other health advantages, making it a considerable discover for clinical research and item development. Continue…. Link Here⬇️ https://lnkd.in/gaN5UF_b JUNE 19, 2024, 1:47 AM #cannabinoid #cannabis #researchanddevelopment #THCP #CBDP

42

20 comentários

BIG NEWS COMING SOON!!! Cannabis Research Coalition is expanding! 😅 As one of the only global #CannabisCultivationResearch orgs we stand a the brink of new innovation, technologies, and efficient growing protocols/methods that are immediatly applicable to the #growers. We are looking for new #members to financially support the needed research! If you want to learn more about what we do, why membership matters and how to get involved- DM me and let’s talk shop. There are plenty of universities also doing cultivation research but it’s discovery work that is not immediately applicable to growers and due to limited funding and academia limitations/restrictions it’s often a slow process Most importantly the industry is not involved much in the academic research- we work directly with some of the worlds largest growers to understand their direct needs to direct our research priorities, this is incredibly valuable! Our team and current members have the experience and arsenal of resources to support the industry’s ever changing needs. We hope to hear from you! Www.cannabisrc.org Allison Justice, PhD. Selina LaBlanche Samuel Wallace Markus Roggen Miyabe Shields, PhD Riley D. Kirk, PhD

74

10 comentários

Jini Glaros, M.S., sheds light on "Moisture Analysis for Cannabis Flower – Understanding Water Content" at CannMed 24. The cannabis industry targets a moisture content of 10% - 14% for cannabis flower, but the standard method may yield inaccurate results due to volatile compounds. Their lab's extensive study compared various moisture determination techniques on over 100 cannabis samples, including LoD, Karl Fisher, vacuum oven, and desiccation methods. A subset of samples was also evaluated for cannabinoid and terpene content pre and post moisture analysis, revealing insights into decarboxylation and terpene loss. This research aims to establish a reliable standard for measuring moisture content in cannabis flower, ensuring accurate values that reflect only water content. Discover more about CannMed and stay informed: https://cannmedevents.com/ Watch the presentation here: https://lnkd.in/evKuf7kP SAVE THE DATE: CannMED 25 June 17th-20th Location: Puerto Rico Resort: https://lnkd.in/dvVGBHm4 CannMed Events Medicinal Genomics Modern Canna Laboratories Discover Puerto Rico

37

💰 Have you ever heard of Total Cost of Ownership (TCO) and wondered why it matters? 📊 Understanding #TCO is essential for optimizing your cannabis cultivation investments. The right nutrients, biostimulants, and biologicals directly affect your bottom line. Cultivators growing with Advanced Nutrients US LLC are increasing their profits $300-$700 per pound by integrating #science backed commercial cultivation solutions. For example, let’s take a look at Cookies. They recently switched back to Advanced Nutrients and are making an additional $400 per pound and yielding 2.5 pounds per light. That’s $1,000 more profit per light. Currently running 1,000 lights, Cookies is on track to make an additional $5.5m just this year. Mike Tuna, their head grower, was using Advanced Nutrients before. Curious to get an edge like any grower would (including myself), decided to test out every product currently on the market. When he returned to Advanced Nutrients, Mike Tuna brought Cookies Maywood: • An extra $1,000 in crop revenue per light 💸 • An additional million dollars per crop 💰 • A staggering $5,500,000 (yes, $5.5 MILLION) per year in extra revenue 🔺 Bottom line: their ROI with #AdvancedNutrients is a whopping 26.31X — THAT is why TCO is so important. Yesterday, we launched the Growroom Showroom Program, seeking 17 elite cultivation facilities to join us as exclusive National Strategic Partners. Partners will showcase their grow rooms, while unlocking unprecedented income streams and sustainable #TotalCostOfOwnership through superior yields. 🤝 How? You’ll earn quarterly #commissions on every sale from showcasing your facility—no inventory needed! Plus access to the best genetics, insights from leading scientists, and our world-class cultivation specialists 24/7 to support your operations at new heights. While you focus on cultivating excellence. 🏆 We only have room for 17 National Strategic Partnerships in the next 30 days. Apply for your spot here now: https://buff.ly/4eCRGRm #AdvancedNutrients #CannabisInvestment #CannabisBusiness #Cannabis #Cultivation #Investment #ROI #CannabisScience #CannabisNutrients #CannabisGrow #CommercialCultivation #CannabisIndustry #Strategic #Partnership

71

7 comentários

🐓 Portugal’s Cannabis Exports Surge: German Legalisation Fuels Rapid Growth Portugal has shattered new records by exporting over 18 tonnes of flower and extracts in the first nine months of 2024. By year-end, exports are set to exceed 25 tonnes, cementing the Lusitan position as the world's second-largest cannabis exporter, trailing only behind Canada. This success is built on Portuguese core strengths: 🌞 Exceptional natural and human conditions 🚚 Strategic role as a supply hub for EU market access 🏛️ Adaptative regulations supporting diverse business models However, a significant gap remains: the very limited domestic access. Only a few hundred packages are distributed monthly, and prescriptions have dropped 33% in the last reported period. Despite a population of just 10 million, building sustainable local demand is essential to reduce risks, diversify revenue streams, accelerate innovation, and drive synergies in patient care, clinical research, and product development. Portugal’s success will continue to be export-driven for the foreseeable future, with European trading partners leading the way: 🥇 Germany: Nearly half of Portugal’s exports head to Germany, with the April 1st legalisation boost driving demand for Portuguese products. 🥈 United Kingdom: It is estimated that around a fifth of Portuguese produce is bound for the growing UK market. 🥉 Poland: Portugal supplies about a sixth of its exports to Poland, with a surge in new product registrations. Additional, albeit smaller markets for Portuguese production include Australia and Israel, while Spain plays a critical supply chain role through Curaleaf’s manufacturing facility and the irradiation plant of Ionisos. Portugal’s dynamic regulatory framework has spurred innovation, fostering almost 50 licensed entities with a variety of business models: ↕️ Vertically-integrated players like Curaleaf International, Tilray Medical Europe or SOMAÍ Pharmaceuticals. 👨‍🌾 EU-GMP producers like Herdade das Barrocas, CANNPRISMA Enhanced Medical Cannabis, Gro-Vida or GreenBe Pharma. ⚙️ Processors, copackers, extractors and service providers like Portocanna and Blossom, along with a collection of nurseries, GACP growers, etc. This diversity in approaches reflects the knife-edge competition driving innovation and market success. ✨ Parabéns to the Portuguese cannabis industry for its impressive progress in recent years. As the international markets continue to evolve in 2025 and beyond, Portugal is well-positioned for even greater growth opportunities. What's your take on Portugal's rapid export-led industry ascent? 🌍 If you found this insight valuable, give it a like 👍 and share 🔄 to help others stay informed! For more in-depth data and insights subscribe to our intelligence brief in the comments below 👇

163

9 comentários

The majority of people said they are investing in Cannabis Biotech and Genetics! Now the followup question: who are you? If you are indeed investing in genetic innovations in hemp and cannabis - please leave a comment, shoot a DM, or send an email to [email protected]! S3 Genetics would love to show you how we are making cannabis and hemp production sustainable. Cheaper for cultivators, better for the environment - a true win-win! #BetterCannabisThroughScience

37

7 comentários

If pesticides were the actual cause of CHS, then: Why doesn't everyone who consumes that weed get CHS? Why do CHS symptoms continue for months and months after last use? Why do certain foods/drinks trigger symptoms/episodes, even years after development? Why don't the symptoms of CHS match with pesticide poisoning? Symptoms of inhaled pesticides include respiratory distress, and that's not a CHS symptom. Severe abdominal pain is also common in CHS, but not in pesticide poisoning. Why do people still have symptoms/episodes with homegrown and organic weed? Why would clean CBD or Marinol trigger symptoms? Dirty weed is absolutely problematic, but so many things don't match up with pesticide poisoning. Claims like this completely invalidate the lived experience of tens of thousands of people suffering with CHS who have tried changing to clean sources, synthetic sources, and are STILL suffering. This platform is one giant echo chamber in denial that overconsumption of THC is actually a problem. Invitation to join the chs fb groups and learn the lived experiences of real people suffering and learn about the nuances of the symptomatology, and you'll see that it doesn't line up with pesticide poisoning.

7

2 comentários

The Michigan Cannabis Regulatory Agency (MI-CRA) "...gave strong consideration to the bidders ability to prevent fraud, abuse, and other unlawful and prohibited activities..." What??? As a laboratory consultant who works exclusively in the #cannabis industry, I believe #outcomes and #value are far superior to a slick sales pitch and low price. Since 2017, the only feedback I have heard from my Michigan cannabis business clients is that fraud, abuse, and illegal activities are rampant and have only accelerated. That doesn't seem like a desired outcome. Many exceptionally talented scientists and businesspeople I’ve worked with to establish and grow their laboratory businesses have suffered life-altering economic losses and barriers to future employment. They chose to stand against consumer fraud, ultimately closing their #laboratories and vaporizing several million dollars of investment along with years of backbreaking effort and now get ghosted by any non-cannabis scientific opportunity. That is the antithesis of value. I am strongly pro-MI CRA and fully acknowledge the complexity and difficultly of their mandate, but IMHO neither the published outcomes nor value appear to match the KPI's for this software selection.

19

6 comentários

The comment period just ended for the recent Cannabis Species Inflorescence Proposed Draft Monograph from the USP. The newest proposed monograph tightened the range of THC and CBD to 90 - 110% of the labeled amount. This is in alignment with most drug products but could be a challenge with the inherent variability of plant material. Another change to the monograph is the addition of a second option for microbial limits. The second option has significantly tighter limits for at risk populations such as immunocompromised patients. Not sure if the intent is to label product for different patient populations. Curious to hear thoughts on how this would be implemented! https://lnkd.in/gfGE6F6p

10

1 comentário

New York Legal Cannabis Market Trends Analysis Report 2024-2030: Approval of the U.S. Farm Bill Expected to Boost Growth. The New York legal cannabis market size is expected to reach USD 3.22 billion by 2030, registering a CAGR of 15.3% from 2024 to 2030 Factors such as the legalization of medicinal cannabis, rising consumer disposable income, increasing consumer awareness of the health benefits of cannabis, growing demand for cannabis from the pharmaceutical industry, and the approval of the U.S. Farm Bill are expected to boost market growth. Cannabis is utilized for managing a range of ailments, including mental health issues, cancer, nausea, and pain, and for adult use purposes. The increasing prevalence of cancer is expected to significantly contribute to the increasing acceptance of medical marijuana over the forecast period. For instance, according to data published by the Government of New York, annually 116,000 New Yorkers are diagnosed with cancer. #Cancer #drugpolicy #Cannabis #cannabisindustry #Newyork #America #goverment #mentalhealth September 20th, 2024 Continue reading link in comment section. 🔽

11

1 comentário

You're raising some critical points about the California medicinal cannabis industry and its complexities. The industry operates within a framework that classifies it as agricultural, regulated by multiple agencies under the California Department of Food and Agriculture (CDFA). Even though cannabis is legal in California for both medical and recreational use, it remains federally illegal, which creates a complicated legal environment—particularly for businesses that fail to comply with state regulations. Your concerns highlight that a significant portion of sellers in this industry may be offering products that aren't safe for human consumption, potentially including toxic substances. This raises important questions about product quality and consumer safety. Compliance is crucial; without proper adherence to safety standards—such as lab testing for contaminants, pesticides, and potency—consumers could be exposed to harmful products. Moreover, if the buildings and facilities where these products are cultivated and processed aren't compliant with local regulations, it compounds the issue. The lack of enforcement could lead to a situation where businesses are operating in a quasi-illegal framework, risking legal repercussions such as actions under the Racketeer Influenced and Corrupt Organizations (RICO) Act. In light of these challenges, what do you think could be implemented to enhance compliance and ensure consumer safety across the industry? The agricultural marketing cooperative Norcal CGA.

2

In the spirit of transformation, let’s focus on the heart of the cannabis industry-the community. The true driving force of this industry. Lessons we've learned from the end of alcohol prohibition, it’s clear that lasting change is rooted in collective action and shared voices. Your experiences and insights are crucial as we advocate for a structured and equitable industry. If your attending #Benzinga I’m eager to connect with industry leaders to discuss how we can shape a future that honors our collective vision. Reach out and let's connect. Not everyone will share the same perspective, but to effectively drive change, we must unite behind a common mission and unified vision. #RescheduleNow #Fuck280e #PayALivingWage #CannabisCommunity #1U #IBTCannabis #TimeIsNow #Teamsters #FightTogetherWinTogether

18

1 comentário

This is why none of my American friends and family know the benefits of CBD! "Medicinal Cannabis: Comparing FDA and ANVISA's Approach to Doctor-Led Oversight" The disparity between how the FDA in the United States and ANVISA in Brazil approach the regulation of medicinal cannabis highlights key differences in both policy frameworks and cultural perspectives on healthcare governance. In the U.S., the FDA classifies cannabis as a Schedule I substance under the Controlled Substances Act, which means it’s federally deemed to have "no accepted medical use." This restricts medical professionals from prescribing it in the traditional sense and means the FDA doesn’t endorse its medicinal use. Instead, access to cannabis-based products is left largely to individual states, with doctors typically offering “recommendations” rather than prescriptions. In contrast, Brazil’s regulatory approach, spearheaded by ANVISA, places clear authority in the hands of medical professionals to oversee cannabis-based treatments. ANVISA has established regulations that allow doctors to prescribe certain cannabis products for specific conditions. Since 2019, ANVISA has approved various cannabis-based medicinal products, though with strict guidelines. Brazilian regulations assume that physicians play a direct role in supervising patient use, aligning more closely with the structure used for conventional medications. This underscores a medicalized view where cannabis treatment requires the direct approval of a healthcare provider, reflecting the belief that all medications, including cannabis, should have formal oversight by trained professionals. The difference stems from both agencies’ distinct perspectives on cannabis's place in medicine. The FDA’s stance reflects longstanding federal policies that restrict cannabis due to its classification and the absence of FDA-approved clinical trials. As a result, U.S. doctors have less control over cannabis recommendations, limiting their role in dosage and treatment management. ANVISA, on the other hand, has taken a more progressive stance, focusing on regulated medical access through trained professionals, in part due to public pressure and growing recognition of cannabis’s therapeutic potential. This centralized and physician-led approach by ANVISA ensures that treatment aligns with Brazil's regulatory standards for medication, while also placing a high level of responsibility on healthcare providers to guide patients through cannabis use in a structured way. #MedicinalCannabis #CannabisRegulation #ANVISA #FDA #CannabisInMedicine #HealthcarePolicy #MedicalCannabis #CannabisBrasil #CannabisUSA #CannabisLaws #DoctorApproved #CannabisResearch

5

“A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Whole Plant Extracts of Cannabis in Cancer“ • investigational product consisted of two standardised and quality-assured specially formulated oil-based organic WHOLE PLANT EXTRACTS of CANNABIS based on : 1:1  THC 4.6mg/ml:CBD 4.8mg/ml  4:1  THC 15mg/ml:CBD 3.8mg/ml • from baseline to week 12 found that the 1:1 ratio favoured both physical (p=0.025) and functional (p=0.014) capacity and improved sleep (p=0.009). •  Analysis of changes from baseline to week 12 also found ; 11% of 61 participants had a reduction in disease  34% were stable  16% had slight enhancement  10% had progressive disease • No serious adverse events occurred. Side effects included dry mouth, tiredness at night, dizziness, drowsiness • study demonstrated that a single nightly dose of THC-containing medicinal cannabis was safe, had no serious adverse effects and was well tolerated in patients. Medicinal cannabis significantly improved sleep, functional wellbeing, and quality of life https://lnkd.in/eTCW77KY

26

1 comentário